To hear about similar clinical trials, please enter your email below

Trial Title: Radical Hypofractionated Radiotherapy for Localized Prostate Cancer

NCT ID: NCT06325774

Condition: Localized Prostate Cancer

Conditions: Official terms:
Prostatic Neoplasms

Study type: Interventional

Study phase: N/A

Overall status: Recruiting

Study design:

Allocation: N/A

Intervention model: Single Group Assignment

Primary purpose: Treatment

Masking: None (Open Label)

Intervention:

Intervention type: Radiation
Intervention name: Hypofractionated radiation therapy
Description: 54 Gy in 15 daily fractions of 3.6 Gy to the prostate bed in the absence of disease progression or unacceptable toxicity.
Arm group label: Hypofractionated Radiotherapy

Summary: The aim of this trial is to study the safety outcomes of hypofractionated radiotherapy in treating patients with localized prostate cancer. Hypofractionated radiotherapy delivers higher doses of radiotherapy in a shorter time period, may enabling the killing of more tumor cells with fewer side effects. Accumulating evidence has proven the safety and feasibility of hypofractionated radiotherapy for localized prostate cancer.But for localized prostate cancer,the optimal dose per fraction of hypofractionated radiotherapy is still on its way.

Detailed description: The present study will be conducted as a prospective, open-label, single-arm clinical trial. The patients will receive hypofractionated radiation(54 Gy in 15 daily fractions of 3.6 Gy ). After completion of study treatment, patients were followed up once a month for the first 3 months and once every 3 months after 3 months for a total of 5 years. The primary endpoints of the study are the toxicities about gastrointestinal (GI),genitourinary (GU) symptoms and erectile dysfunction.The secondary endpoints include progression-free survival (bPFS), local progression-free-survival(LPFS) ,distant metastasis free survival(DMFS) ,overall survival (OS)and quality of life (QoL).

Criteria for eligibility:
Criteria:
Inclusion Criteria: - Age: ≥18 years old; - European Cooperative Oncology Group score(ECOG):≤ 2; - Patients with pathologically diagnosed prostate cancer; - Clinical stage was cTanyN0M0 any Gleason / ISUP group; - Expected survival time >5 years; - The patient has no contraindications to radiotherapy and is suitable and willing to undergo radiotherapy; - Patients who voluntarily accept the experimental study protocol after being informed about the existing treatment options; Exclusion Criteria: - Patients who have received any other early treatment for prostate cancer, including radiotherapy, chemotherapy, focal therapy, etc; - a previous history of pelvic and abdominal radiotherapy; - Prior hormonal therapy (castration or antiandrogen); - Patients with other malignancies and acute or chronic infections such as human immunodeficiency virus (HIV) (+), hepatitis C virus (HCV) (+) and/or positive syphilis; - Patients that the investigator considers unsuitable to participate in the clinical trial; patients with other serious systemic diseases, evaluation and compliance of the trial, including severe respiratory, circulatory, neurological, mental, digestive, endocrine, immune, urinary, and other systemic diseases; - Patients with contraindications related to radiotherapy; - Participate in other clinical trials that are mutually exclusive with the study intervention within 4 weeks prior to the start of the study; - Patients unable to provide written informed consent or demonstrate poor treatment compliance

Gender: Male

Minimum age: 18 Years

Maximum age: N/A

Healthy volunteers: No

Locations:

Facility:
Name: Changhai hospital

Address:
City: Shanghai
Zip: 200433
Country: China

Status: Recruiting

Contact:
Last name: Huojun Zhang, M.D.

Phone: +8613311732399
Email: chyyzhj@163.com

Investigator:
Last name: Huojun Zhang, M.D.
Email: Principal Investigator

Start date: September 1, 2024

Completion date: September 1, 2031

Lead sponsor:
Agency: Changhai Hospital
Agency class: Other

Source: Changhai Hospital

Record processing date: ClinicalTrials.gov processed this data on November 12, 2024

Source: ClinicalTrials.gov page: https://clinicaltrials.gov/ct2/show/NCT06325774

Login to your account

Did you forget your password?